Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer ; volume:41 ; number:8 ; day:1 ; month:8 ; year:2023 ; pages:2091-2097 ; date:8.2023
World journal of urology ; 41, Heft 8 (1.8.2023), 2091-2097, 8.2023
- Urheber
-
Rebhan, Katharina
Stelzer, Philipp D.
Pradere, Benjamin
Rajwa, Pawel
Kramer, Gero
Hofmann, Bernd
Resch, Irene
Yurdakul, Ozan
Laccone, Franco A.
Bujalkova, Maria Gerykova
Smogavec, Mateja
Tan, Yen Y.
Ristl, Robin
Shariat, Shahrokh F.
Egger, Gerda
Hassler, Melanie R.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00345-023-04535-4
- URN
-
urn:nbn:de:101:1-2023110209390993078154
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rebhan, Katharina
- Stelzer, Philipp D.
- Pradere, Benjamin
- Rajwa, Pawel
- Kramer, Gero
- Hofmann, Bernd
- Resch, Irene
- Yurdakul, Ozan
- Laccone, Franco A.
- Bujalkova, Maria Gerykova
- Smogavec, Mateja
- Tan, Yen Y.
- Ristl, Robin
- Shariat, Shahrokh F.
- Egger, Gerda
- Hassler, Melanie R.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Medical practice and placebo response: an inseparable bond?
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
MRI as a screening tool for prostate cancer: current evidence and future challenges
Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology Images
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Medical practice and placebo response: an inseparable bond?
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
MRI as a screening tool for prostate cancer: current evidence and future challenges
Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology Images
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Medical practice and placebo response: an inseparable bond?
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
MRI as a screening tool for prostate cancer: current evidence and future challenges